Silexion Therapeutics Corp (SLXN)
| Market Cap | 3.83M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.36M |
| Shares Out | 8.32M |
| EPS (ttm) | -9.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 989,874 |
| Open | 0.510 |
| Previous Close | 0.534 |
| Day's Range | 0.455 - 0.523 |
| 52-Week Range | 0.455 - 13.560 |
| Beta | -0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 21, 2024 |
About SLXN
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre... [Read more]
News
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)---- $SLXN #BioTech--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) t...
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
Silexion Therapeutics Corp. SLXN stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER.
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)---- $SLXN #BioTech--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) t...
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
LONDON--(BUSINESS WIRE)---- $MACA #KRAS--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RN...
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company today announced that...
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
The combined company's shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024 The combined company's shares and warrants are ...
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa”), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. (“Silexion”), a clin...
MORINGA ACQUISITION CORP ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION
New York, NY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa” or the “Company”) announced today that, in connection with its previously announced extraordinary gen...